Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos GroupASX:EBO -0.64%80 14-Day RSI is 68.53 as of Jul. 15, 2026. GuruFocus rates ASX:EBO with a GF Score™ of 80/100 and a GF Value™ of A$31.55 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 124 Medical Distribution companies, Ebos Group ranks worse than 91.94% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-15), Ebos Group's 14-Day RSI is 68.53.
The industry rank for Ebos Group's 14-Day RSI or its related term are showing as below:
ASX:EBO's 14-Day RSI is ranked worse than 91.94% of 124
companies
in the Medical Distribution industry
Industry Median: 50.54
vs ASX:EBO: 68.53
Ebos Group (ASX:EBO) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Ebos Group 14-Day RSI Related Terms
ASX:EBO vs MCK, CAH, COR: 14-Day RSI Comparison
For the Medical Distribution subindustry, Ebos Group's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group 14-Day RSI vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Ebos Group's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ebos Group (ASX:EBO) has a 14-Day RSI of 68.53 as of Jul. 15, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Ebos Group and its competitors. According to the industry distribution chart, Ebos Group ranks #114 out of 124 companies in the Medical Distribution industry, placing it in the top 91.9%.
Is Ebos Group's 14-Day RSI too high?
Ebos Group's current 14-Day RSI is 68.53. The Medical Distribution industry median 14-Day RSI is 50.54. Ebos Group's value of 68.53 is 35.6% above this industry median. Based on the distribution chart, Ebos Group ranks #114 out of 124 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Ebos Group has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's 14-Day RSI compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #114 out of 124 companies for 14-Day RSI. This places Ebos Group in the lower half of its industry. The industry median 14-Day RSI is 50.54. Ebos Group's value of 68.53 is 35.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Distribution company?
The median 14-Day RSI among Medical Distribution companies is 50.54, based on 124 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current 14-Day RSI of 68.53 is 35.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median 14-Day RSI is 50.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current 14-Day RSI is 68.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$31.55, compared to a current price of A$18.68 — trading 40.8% below its estimated fair value. The current 14-Day RSI is 68.53 and 35.6% above the Medical Distribution industry median of 50.54. Ebos Group's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current 14-Day RSI is 68.53 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (ASX:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of A$18.68 is trading 40.8% below its estimated GF Value™ of A$31.55.
GuruFocus considers Ebos Group to be Significantly Undervalued.
Key valuation signals for ASX:EBO:
14-Day RSI: 68.53
GF Value™: A$31.55 vs. price of A$18.68 (40.8% below fair value)
Industry Position: 35.6% above the Medical Distribution median (#114 of 124)
No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
80GF Score
Get the complete analysis for ASX:EBO
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EBO has been successfully added to your 
